Atazanavir Sulfate Capsule
FDA Label NDC 0093-5527

49 label sections · Submitted to the FDA by Teva Pharmaceuticals Usa, Inc. · Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Teva Pharmaceuticals Usa, Inc. for the product Atazanavir Sulfate (NDC 0093-5527). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding 1 indications and usage, 2.1 overview, 2.2 testing prior to initiation and during treatment with atazanavir capsules, 2.3 dosage of atazanavir capsules in adult patients, 2.4 dosage of atazanavir capsules in pediatric patients, 2.6 dosage adjustments in pregnant patients, 2.7 dosage in patients with renal impairment, 2.8 dosage adjustments in patients with hepatic impairment, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

Label Section Quick Index

* Please review the disclaimer below.